Prevention by dexrazoxane of down‐regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat

Authors:

Abstract
Anthracyclines can cause cumulative dose‐related cardiotoxicity characterized by changes in Ca2+ metabolism, including dysfunction of the sacroplasmic reticulum (SR) and decreased expression of Ca2+‐handling proteins, such as the ryanodine receptor (RyR2). In this study, we examined the effect of dexrazoxane (ICRF‐187), an iron chelator which prevents anthracycline cardiotoxicity, on RyR2 gene expression in rats treated chronically with daunorubicin. Daunorubicin (2.5 mg kg−1 i.v. weekly for 6 weeks) produced cardiotoxicity as demonstrated by histopathologic changes. The ryanodine receptor/glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA ratio was decreased by 38±3% (P−1; 1 h prior to each daunorubicin injection) prevented the decrease in RyR2/GAPDH mRNA ratio and histopathologic lesions in daunorubicin‐treated rats. This is the first report that a protective agent such as dexrazoxane can ameliorate the decreased expression of a specific gene involved in anthracycline‐induced cardiotoxicity.British Journal of Pharmacology (2000) 131, 1–4; doi:10.1038/sj.bjp.0703538

This publication has 13 references indexed in Scilit: